Efficacy of Bisphosphonates on Bone Mineral Density and Fracture Rate in Patients With Osteogenesis Imperfecta

2016 ◽  
Vol 23 (3) ◽  
pp. e894-e904 ◽  
Author(s):  
Chang Gui Shi ◽  
Ying Zhang ◽  
Wen Yuan
Keyword(s):  
Bone Mineral Density ◽  
Osteogenesis Imperfecta ◽  
Bone Mineral ◽  
Fracture Rate ◽  
Mineral Density

Bone Mineral Density and Fracture Rate in Response to Intravenous and Oral Bisphosphonates in Adult Osteogenesis Imperfecta

2010 ◽  
Vol 87 (2) ◽  
pp. 120-129 ◽  
Author(s):  
Jay R. Shapiro ◽  
Carol B. Thompson ◽  
Yimei Wu ◽  
Martin Nunes ◽  
Carolynn Gillen
Keyword(s):  
Bone Mineral Density ◽  
Osteogenesis Imperfecta ◽  
Bone Mineral ◽  
Fracture Rate ◽  
Oral Bisphosphonates ◽  
Mineral Density

Intravenous pamidronate for treatment of osteogenesis imperfecta in Indian children

2021 ◽  
pp. 004947552098269
Author(s):  
Ira Shah ◽  
Akshat Goel ◽  
Naman S Shetty ◽  
Ashok Johari
Keyword(s):  
Bone Mineral Density ◽  
Osteogenesis Imperfecta ◽  
Bone Mineral ◽  
Fragility Fractures ◽  
Bone Fragility ◽  
Fracture Rate ◽  
Spinal Bone Mineral Density ◽  
Mineral Density ◽  
Indian Children ◽  
Intravenous Pamidronate

Osteogenesis imperfecta is characterised by low bone mineral density, bone fragility, fractures and deformity. We present five such children treated with intravenous pamidronate, which resulted in a decrease of fracture rate and increase in spinal bone mineral density.

scholarly journals Craniofacial Bone Mineral Density in Mice with Osteogenesis Imperfecta (OI)

2019 ◽  
Vol 33 (S1) ◽  
Author(s):  
Alexandra H McBride ◽  
Summer H Ladd ◽  
Jason M Organ ◽  
Rachel A Menegaz
Keyword(s):  
Bone Mineral Density ◽  
Osteogenesis Imperfecta ◽  
Bone Mineral ◽  
Mineral Density ◽  
Craniofacial Bone

scholarly journals Bone mineral density in developing children with osteogenesis imperfecta

2013 ◽  
Vol 84 (4) ◽  
pp. 431-436 ◽  
Author(s):  
Dieke H J Kok ◽  
Ralph J B Sakkers ◽  
Hans E H Pruijs ◽  
Pieter Joosse ◽  
René M Castelein
Keyword(s):  
Bone Mineral Density ◽  
Osteogenesis Imperfecta ◽  
Bone Mineral ◽  
Mineral Density

High Bone Mineral Density Osteogenesis Imperfecta in a Family with a Novel Pathogenic Variant in COL1A2

2020 ◽  
Vol 93 (4) ◽  
pp. 263-271
Author(s):  
Lara E. Graves ◽  
Christie-Lee Wall ◽  
Julie N. Briody ◽  
Bruce Bennetts ◽  
Karen Wong ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mass ◽  
Osteogenesis Imperfecta ◽  
Bone Mineral ◽  
Quantitative Computed Tomography ◽  
Diagnostic Process ◽  
Low Bone Mass ◽  
Mineral Density ◽  
Pathogenic Variants ◽  
Minimal Trauma

Osteogenesis imperfecta (OI) is a heterogenous group of heritable bone dysplasias characterized by bone fragility, typically low bone mass, joint laxity, easy bruising, and variable short stature. Classical OI is caused by autosomal dominant pathogenic variants in <i>COL1A1</i> or <i>COL1A2</i> that result in either reduced production of normal type 1 collagen or structurally abnormal collagen molecules. Pathogenic variants in these genes generally result in low bone mass. Here, we report a family that had 2 affected individuals who presented with minimal trauma fractures and were found to have elevated bone mineral density (BMD) and a previously unreported variant in <i>COL1A2</i> c.3356C&#x3e;T p.(Ala1119Val). We report the change in BMD using dual-energy X-ray and peripheral quantitative computed tomography over a 2.3-year period in the proband. This case report highlights the importance of BMD studies and genetic testing in the diagnostic process for brittle bone disorders.

scholarly journals Anticoagulants and Osteoporosis

2019 ◽  
Vol 20 (21) ◽  
pp. 5275 ◽  
Author(s):  
Salvatore Santo Signorelli ◽  
Salvatore Scuto ◽  
Elisa Marino ◽  
Michele Giusti ◽  
Anastasia Xourafa ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Metabolism ◽  
Bone Mineral ◽  
Vitamin K ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Fragility Fractures ◽  
Fracture Rate ◽  
Mineral Density ◽  
Literature Search Strategy

Anticoagulant agents are widely used in the treatment of thromboembolic events and in stroke prevention. Data about their effects on bone tissue are in some cases limited or inconsistent (oral anti-vitamin K agents), and in others are sufficiently strong (heparins) to suggest caution in their use in subjects at risk of osteoporosis. This review analyses the effects of this group of drugs on bone metabolism, on bone mineral density, and on fragility fractures. A literature search strategy was developed by an experienced team of specialists by consulting the MEDLINE platform, including published papers and reviews updated to March 2019. Literature supports a detrimental effect of heparin on bone, with an increase in fracture rate. Low molecular weight heparins (LMWHs) seem to be safer than heparin. Although anti-vitamin K agents (VKAs) have a significant impact on bone metabolism, and in particular, on osteocalcin, data on bone mineral density (BMD) and fractures are contrasting. To date, the new direct oral anticoagulants (DOACs) are found to safe for bone health.

The effect of aromatase inhibitors on bone mineral density measured by serial DXA scans

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 11065-11065 ◽  
Author(s):  
K. J. Whannel ◽  
J. C. Doughty ◽  
C. R. Wilson ◽  
A. McLellan
Keyword(s):  
Bone Mineral Density ◽  
Endocrine Therapy ◽  
Bone Mineral ◽  
Aromatase Inhibitors ◽  
Fracture Rate ◽  
Mineral Density ◽  
First Line ◽  
Dxa Scan ◽  
T Score ◽  
Dxa Scans

11065 Background: We are now using aromatase inhibitors (AI) in increasing numbers of women as treatment in the breast cancer care pathway. Studies have reported a loss of bone mineral density (BMD) with use of all AIs. It has been shown in our unit that 5 years of tamoxifen (T) in post-menopausal women prior to commencing an AI does not offer sufficient protection to prevent significant BMD loss when an AI is introduced, with 25% requiring concurrent bisphosphonate (BP) therapy. The aim of this study was to determine changes in serial DXA scan results over a 12month period in women taking AIs. Method: 62 women being considered for or in early stages of use of an AI attended for a DXA scan and re-scan at 12 months. Vertebral morphometry and fracture rate were assessed and risk factors for osteoporosis noted. Scan results were compared ( Table 1 ). Results: Mean age was 67yrs [standard deviation (SD) 9yrs]. The patients were grouped according to initial endocrine therapy. 13 (21%) switched from tamoxifen to arimidex after 2years, 3 (4.8%) switched from tamoxifen to exemestane after 3 years and 30 (48.4%) switched from tamoxifen to letrozole after 5 years. 11 (17.7%) had been on arimidex as first line endocrine therapy for <=2 years and 5 (8.1%) had been on letrozole as first line endocrine therapy for <=1 year. Mean t-score and SD was calculated at each site and results categorised by lowest t-score at any site. The overall decrease in BMD measured at 1.66% over the 12 months. Conclusion: We have demonstrated a decrease in BMD with AI treatment of 1.66% per year as well as an increase in fracture incidence and increased need for bisphosphonate therapy whilst on an AI. We would recommend that all patients on any AI receive annual DXA scans. [Table: see text] No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document